AbCellera to Participate at Upcoming Investor Conferences in March
Get Alerts ABCL Hot Sheet
Join SI Premium – FREE
VANCOUVER, British Columbia--(BUSINESS WIRE)-- AbCellera (Nasdaq: ABCL) today announced that the Company will participate in the following investor conferences:
- 45th Annual TD Cowen Health Care Conference, March 3-5
- KeyBanc Capital Markets Healthcare Forum, March 18-19
Visit AbCellera's Investor Relations website for additional information.
About AbCellera Biologics Inc.
AbCellera (Nasdaq: ABCL) discovers and develops antibody medicines for indications across therapeutic areas including cancer, metabolic and endocrine conditions, and autoimmune disorders. AbCellera’s engine integrates technology, data science, infrastructure, and interdisciplinary teams to solve the most challenging antibody discovery problems. AbCellera is focused on advancing an internal pipeline of first-in-class and best-in-class programs and collaborating on innovative drug development programs with partners. For more information, please visit www.abcellera.com.
View source version on businesswire.com: https://www.businesswire.com/news/home/20250211013862/en/
Inquiries
Media: Tiffany Chiu; [email protected], +1(604)724-1242
Business Development: Murray McCutcheon, Ph.D.; [email protected], +1(604)559-9005
Investor Relations: Peter Ahn; [email protected], +1(778)729-9116
Source: AbCellera Biologics Inc.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- ComEd Debuts Mobile Assistance Unit at Waukegan Resource Fair, Bringing On-Site Bill Help Directly to Customers
- AI Memecoin Trading 2026: Why Automated Agents Are Becoming the Future of Meme Markets
- FIA Celebrates Over Ninety Years of Supporting Motor Sport in the United States at the INDYCAR Freedom 250 Grand Prix of Washington D.C.
Create E-mail Alert Related Categories
Business Wire, Press ReleasesRelated Entities
KeyBanc, Cowen & CoSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!



Tweet
Share